Funding associated with investigation or inquiry that may lead to the creation or use of Intellectual Property

Funding associated with the creation of new, breakthrough or disruptive science or technology

Funding that requires collaboration between industrial and academic partners

Funding or support to prove the market value, function or application of a product or service idea

Funding or support related to the design and manufacture of a prototype product or system

Funding or support related to the design processes associated with the product development cycle

Funding or support related to manufacture, supply chain, or design for manufacture , or reducing costs

Funding or support related to the design and development processes, related to product commercialisation

Funding or support associated with "selling" a product or service, or increasing revenues

Funding or support associated with the early stages of company formation and growth

Funding or support associated with skills, training or employee development

Funding or support to assist companies to globalise or internationalise their products or services

Amgen Ventures

 

Amgen Ventures funds early-stage companies developing human therapeutics. While the fund’s focus is primarily in areas of current therapeutic interest to Amgen, we also seek out novel modalities with the potential to address targets in both current and emerging therapeutic areas of interest. The fund considers important technology breakthroughs that may provide the opportunity to advance the creation of human therapeutics.

In 2004, Amgen announced the formation of Amgen Ventures, a corporate venture capital fund. With an initial investment of $100 million, the fund is designed to provide emerging biotechnology companies with resources to develop pioneering discoveries focused on human therapeutics. Amgen Ventures reflects Amgen's commitment to helping patients by transforming cutting-edge scientific discoveries into novel treatments for serious illness.

As an important component of Amgen’s overall outreach strategy, Amgen Ventures invests in early-stage biotechnology companies focused on discovering and developing human therapeutics. The fund, which focuses primarily on areas of current therapeutic interest to Amgen, offers early-stage companies access to our extensive capabilities while providing us with insight into external research innovations that may pave the way for future collaborations.

Therapeutic Areas of Interest:

Oncology & Hematology

Nephrology

Inflammation

Cardiovascular

Metabolic Disorders

Neuroscience

Discovery Research and Technology

Please contact Amgen Ventures for more information

http://www.amgen.com/pdfs/misc/Amgen-Ventures-Overview.pdf